Overview
Replimune was founded in 2015 to pioneer a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response. Oncolytic immunotherapy is expected to enhance the effectiveness of immune checkpoint blockade and become the second cornerstone of immune-oncology approaches, moving beyond incremental improvement in cancer treatment to help more patients overcome their disease. Replimune is headquartered in Woburn, MA and is building out a manufacturing facility in Framingham, MA.